Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors

This study will capitalize on technologies that can detect the presence of t-CH at very low levels to determine whether such clones emerge from therapy, expand over time and whose presence correlate with early signs of CVD as detected by cardiac MRI.

Inclusion Criteria:Enrolled and completed therapy on AHOD1331.Not known to have had a primary event (relapse/second malignancy/death). Note: Subjects enrolled and/or treated on AHOD1331 at another institution are eligible if they are now being followed at the current COG institution.Patient must have access to cardiac MRI at institution where receiving follow-up care and must be able to complete cardiac MRI without sedation.All patients and/or their parents or legal guardians must sign a written informed consent.All institutional, FDA, and NCI requirements for human studies must be met.Exclusion Criteria:Medical contraindication to undergoing a cardiac MRI.Removed from AHOD1331 therapy prior to completing the AHOD1331 protocol specified treatment plan.Received cancer therapy in addition to that of AHOD1331 (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).History of cardiovascular disease prior to enrollment on AHOD1331.